[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1315 Introduced in House (IH)]
<DOC>
118th CONGRESS
1st Session
H. R. 1315
To amend the Public Health Service Act to establish a Prostate Cancer
Coordinating Committee, and for other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
March 1, 2023
Mr. Murphy introduced the following bill; which was referred to the
Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To amend the Public Health Service Act to establish a Prostate Cancer
Coordinating Committee, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Prostate Cancer Community
Assistance, Research and Education Act of 2023'' or the ``PC-CARE
Act''.
SEC. 2. FINDINGS.
Congress finds the following:
(1) Prostate cancer is the most commonly diagnosed non-skin
cancer and the second leading cause of cancer-related deaths
among men in the United States.
(2) Over 3,100,000 men in the United States live with a
prostate cancer diagnosis and it is estimated that in 2023,
288,300 men will be diagnosed with, and more than 34,700 men
will die of, prostate cancer.
(3) Men with at least one close relative who has been
diagnosed with prostate cancer have twice the risk of having
prostate cancer compared to the general population.
(4) At least 12 percent of men with metastatic prostate
cancer have inherited predispositions to the disease and
potentially actionable genomic alterations have been identified
in over 90 percent of men with metastatic castration-resistant
prostate cancer.
(5) Advances in science to identify, test, and treat these
men at increased genetic risk of disease are needed.
(6) African-American men suffer from a prostate cancer
incidence rate that is significantly higher than that of White
men and have more than double the prostate cancer mortality
rate than that of White men.
(7) Research has shown that veterans exposed to herbicides,
such as Agent Orange, are at higher risk for and more likely to
be diagnosed with aggressive forms of prostate cancer.
(8) Screening by a digital rectal examination and a
prostate-specific antigen blood test can detect the disease at
the earlier, more treatable stages.
(9) Men diagnosed with early stage disease have a nearly
100 percent 5-year survival rate but only 30 percent of men
survive more than 5 years if diagnosed with prostate cancer
after the cancer has metastasized.
(10) Early-staged prostate cancer has no symptoms, raising
the importance of early detection and screening.
(11) The Department of Health and Human Services, the
Department of Defense, and the Department of Veterans Affairs
all have a role in providing care for and conducting research
on prostate cancer.
(12) Multiple institutes at the National Institutes of
Health are engaged in prostate cancer care and research,
including the National Cancer Institute, National Institute of
Biomedical Imaging and Bioengineering, the National Institute
on Minority Health and Health Disparities, and the Clinical
Center.
(13) Additional agencies and offices within the Department
of Health and Human Services conduct activities related to
prostate cancer, including the Centers for Medicare and
Medicaid Services, the Centers for Disease Control and
Prevention, the Food and Drug Administration, the Health
Resources and Services Administration, the Office of Minority
Health, and the Agency for Healthcare Research and Quality.
(14) The Department of Defense created the Prostate Cancer
Research Program in 1997 and has funded more than
$2,000,000,000 in prostate cancer research since that time.
(15) Private foundations have provided substantial funding
to the prostate cancer research community for almost three
decades, including support for over 200 cancer centers and
universities.
(16) The Director of the National Institutes of Health has
partnered with private prostate cancer research groups to study
to study biological and nonbiological factors associated with
aggressive prostate cancer in African-American men.
(17) The Secretary of Veterans Affairs has partnered with
private foundations to establish precision oncology program
hubs for prostate cancer.
(18) The Director of the Centers for Disease Control and
Prevention has partnered with multiple private stakeholder
groups to increase awareness and education around prostate
cancer in the general population and among high-risk groups.
(19) Increased coordination of governmental and
nongovernmental activities can reduce costs and increase
effectiveness of ongoing work.
(20) Joint planning and goal setting across the Government
and private sector can create a pathway toward eliminating
prostate cancer deaths and improving care for millions of men.
SEC. 3. PROSTATE CANCER COORDINATING COMMITTEE.
Part A of title IV of the Public Health Service Act (42 U.S.C. 281
et seq.) is amended by adding at the end the following:
``SEC. 404F. PROSTATE CANCER COORDINATING COMMITTEE.
``(a) Establishment.--The Secretary shall establish a committee to
be known as the Prostate Cancer Coordinating Committee (referred to in
this section as the `Coordinating Committee').
``(b) Duties.--The Coordinating Committee shall--
``(1) monitor, coordinate, and evaluate activities with
respect to prostate cancer research programs carried out by
Federal agencies; and
``(2) develop and implement the plan under subsection (g).
``(c) Composition.--
``(1) In general.--The Coordinating Committee shall be
composed of not more than 24 members, to be appointed by the
Secretary, of whom--
``(A) one-half shall represent Federal agencies
that carry out research or treatment activities with
respect to prostate cancer, including--
``(i) the Director of the National
Institutes of Health (or designee);
``(ii) the directors of the appropriate
agencies of the National Institutes of Health
(or designees), including the National Cancer
Institute;
``(iii) the Director of the Centers for
Disease Control and Prevention (or designee);
``(iv) the Administrator of the Health
Resources and Services Administration (or
designee);
``(v) the Administrator of the Centers for
Medicare & Medicaid Services (or designee);
``(vi) the Commissioner of Food and Drugs
(or designee);
``(vii) the Secretary of Defense (or
designee); and
``(viii) the Secretary of Veterans Affairs
(or designee); and
``(B) one-half shall be individuals who have
experience with prostate cancer, including--
``(i) not less than 3 individuals who are
living with prostate cancer (or a caregiver of
such individual);
``(ii) not less than 3 researchers;
``(iii) not less than 3 clinicians;
``(iv) not less than 3 representatives from
patient groups; and
``(v) not less than 3 representatives from
professional medical societies.
``(2) Physician requirement.--Of the members appointed
under paragraph (1), not less than one-half shall be
physicians.
``(d) Term; Vacancies.--
``(1) In general.--A member shall be appointed for a term
of 3 years.
``(2) Vacancies.--A vacancy on the Coordinating Committee
shall be filled in the same manner as the original appointment
was made.
``(e) Reappointment.--The Secretary may reappoint a member of the
Coordinating Committee to an unlimited number of terms.
``(f) Chair.--The Secretary shall appoint the chair of the
Coordinating Committee.
``(g) Plan.--Not later than 1 year after the date of the enactment
of this section, the Coordinating Committee shall develop and implement
a plan (and update such plan every 3 years thereafter), in consultation
with a broad range of scientists, patients, clinicians, and advocacy
groups, on prostate cancer research programs and activities carried out
by Federal agencies. Such plan shall include the following:
``(1) The identification of existing prostate cancer
programs and activities of the--
``(A) the Department of Health and Human Services,
including the National Institutes of Health;
``(B) the Department of Defense; and
``(C) the Department of Veterans Affairs.
``(2) An evaluation on research with respect to the
underlying causes, prevalence, treatment, and mortality of
prostate cancer, including any disparity among African-American
and other high-risk men (defined as men who have a family
history of prostate cancer, a genetic predisposition for
prostate cancer, or developed cancer due to exposure to certain
chemical and radiological agents).
``(3) With respect to prostate cancer--
``(A) an evaluation on the effectiveness of current
screening and diagnostic techniques; and
``(B) recommendations for improving such
techniques.
``(4) An evaluation on the effectiveness of treatments for
prostate cancer and the development of recommendations for new
treatments, including new biological agents.
``(5) With respect to prostate cancer, an evaluation on the
effectiveness of clinical practice guidelines and the
development of recommendations to improve such guidelines.
``(6) The development of recommendations to improve
clinical pathways in private and government-operated medical
systems, including screening and diagnosis and information on
informed and shared decision making.
``(7) The development of recommendations for research
investigation methods for improving the quality of life of
individuals who have survived with prostate cancer.
``(8) With respect to prostate cancer, an evaluation on the
effectiveness of information and education programs for health
care professionals and the public.
``(9) With respect to screening and clinical trial
enrollment for prostate cancer, recommendations to improve
outreach and education, including best practices for outreach
to African-American men and other high-risk men.
``(h) Meetings.--The Coordinating Committee shall meet at the
request of the Secretary not less 3 times each year.
``(i) FACA.--Except as provided in this section, the Federal
Advisory Committee Act (5 U.S.C. App.) shall not apply to the
Coordinating Committee.
``(j) Report.--
``(1) Initial report.--Not later than 1 year after the date
of the enactment of this section, the Coordinating Committee
shall submit recommendations using the plan under subsection
(g) to the following:
``(A) The Secretary of the Department of Health and
Human Services.
``(B) The Secretary of Defense.
``(C) The Secretary of Veterans Affairs.
``(D) The Committees on Energy and Commerce and
Appropriations of the House of Representatives.
``(E) The Committees on Health, Education, Labor,
and Pensions and Appropriations of the Senate.
``(2) Updated reports.--Not later than 3 years after the
date of the enactment of this section, and every 3 years
thereafter, the Coordinating Committee shall submit to the
secretaries and committees listed in paragraph (1)--
``(A) updated recommendations using the plan under
subsection (g); and
``(B) a summary of progress made with respect to
recommendations submitted pursuant to this section.
``(k) Authorization of Appropriations.--There are authorized to be
appropriated to carry out this section such sums as may be necessary
for each of fiscal years 2024 through 2030.''.
<all>